Menu

Reimagine their treatment journey with RUKOBIA
MANAGING ADULTS WITH MULTIDRUG-RESISTANT HIV-1 IS CHALLENGING1

REIMAGINE THEIR TREATMENT JOURNEY WITH RUKOBIA

A first-in-class attachment inhibitor

A first-in-class attachment inhibitor that directly targets HIV-1 to protect CD4+ T-cells2

Durable virologic suppression

Durable virologic suppression demonstrated over 5 years3

Robust CD4+ T-cell recovery

Robust and clinically meaningful CD4+T-cell recovery over 5 years3,4

RUKOBIA — A BREAKTHROUGH FIRST-IN-CLASS TREATMENT WITH A NOVEL MOA2

RUKOBIA, as part of an optimised background regimen, is the only therapy developed for people living with MDR HIV-1 clinically proven to offer virologic suppression and CD4+ T-cell recovery over 5 years.2,3

RUKOBIA INCLUDED IN EACS 2023 GUIDELINES

When a 2-3 drugs active regimen cannot be constructed with NRTI, NNRTI, PI/b and INSTI, a drug with a new mechanism of action such as fostemsavir can be selected to obtain such a 2-3 drugs active regimen.5

The many faces of people living with MDR HIV-1

See perspectives from people living with MDR HIV-1

View Now

First-in-class attachment inhibitor

Find out what makes RUKOBIA different from other ARV therapies6

Learn more

Durable 5-year efficacy

Explore the 5-year virologic suppression data for RUKOBIA for people living with MDR HIV-13

See the Data

Breaking news: 240-week BRIGHTE trial results

Dr. Mills shares an exciting announcement about the BRIGHTE 5-year data for RUKOBIA for people living with MDR HIV-13

Watch Video

ARV=antiretroviral; HIV-1=human immunodeficiency virus type-1; INSTI=integrase strand transfer inhibitor; MDR=multidrug-resistant; MOA=mechanism of action; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=nonnucleoside reverse transcriptase inhibitor; PI=protease inhibitor.

RUKOBIA, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.2

References:

  1. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. RUKOBIA Summary of Product Characteristics.
  3. Aberg J, Shepherd B, Wang M, et al. Poster presented at the 24th International AIDS Conference. 29 July – 2 August 2022. Montreal, Canada. EPB160.
  4. Llibre J, Aberg J, Walmsley S, et al. Poster present at the 19th European AIDS Conference (EAC). 18-21 October 2023. Warsaw, Poland. eP.A.093.
  5. EACS Guidelines. Version 12.0. October 2023.
  6. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.

PM-GBL-FST-WCNT-230008 | January 2025

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.